Bachem Holding AG: history, ownership, mission, how it works & makes money

From a two-person startup in Liestal in 1971 to a global biotech specialist headquartered in Bubendorf, Bachem Holding AG's journey is a compelling mix of strategic acquisitions and steady scaling-by 2024 it employed over 2,200 people and reported revenue of CHF 605.3 million; listed on the SIX as BANB with founder Peter Grogg still holding majority influence, the company has bolstered its portfolio through deals such as the 1999 Peninsula Laboratories acquisition and 2007's Clinalfa purchase, while recent governance moves saw shareholders approve a CHF 0.85 per-share dividend in April 2025 with 79.7% of eligible shares represented at the AGM; operationally Bachem focuses on peptide and oligonucleotide process development, manufacturing and regulatory support across sites in Bubendorf, Vionnaz, Vista, Torrance and St Helens, with commercial active ingredients accounting for 57% of 2024 sales and plans to invest over CHF 400 million in 2025 to expand capacity-momentum that produced a 30.2% rise in group sales to CHF 313.0 million and a 64.0% jump in EBITDA to CHF 91.0 million (a 29.1% margin) in H1 2025 as Bachem pursues targets of >CHF 1 billion in annual sales and an EBITDA margin above 30% by 2026, setting the stage for deeper looks at history, ownership, mission, operations and revenue drivers in the full article

Bachem Holding AG (0QND.L): Intro

• Founded: 1971 by Peter Grogg in Liestal, Switzerland (2 employees).
• Headquarters: Bubendorf, Switzerland (relocated 1977; workforce then 8 employees).
• Global footprint: Multiple sites including Switzerland and the U.S. (acquisitions and expansions).

• 1971-1980s: Foundation and early growth in peptide chemistry and custom synthesis.
• 1990s-2000s: International expansion and strategic acquisitions to add product lines and U.S. manufacturing.
• 2010s-2020s: Consolidation of peptide API and specialty biochemical capabilities; greater scale in commercial manufacturing and CDMO services.

• Publicly listed company (ticker presented here as Bachem Holding AG (0QND.L)); governance under a Board of Directors and executive management team.
• Shareholder base: mixture of institutional investors, private shareholders and company insiders; majority exposure through public free float markets.
• Operates via multiple subsidiaries and production sites to deliver integrated services from discovery to commercial supply.

• Mission: Supply high-quality peptides and complex organic molecules to advance pharmaceutical and biotech research, development and commercial therapies.
• Strategic priorities: technology leadership in peptide synthesis, capacity expansion for clinical and commercial manufacturing, vertical integration of R&D and production, and geographic diversification (notably strengthened U.S. presence via acquisitions).

• Core activities: custom peptide synthesis, contract development and manufacturing (CDMO), and sale of catalog peptides/biochemicals for research and diagnostics.
• Value chain: medicinal chemistry & process development → scale-up & GMP manufacturing → quality control/regulatory support → commercial supply & life-cycle services.
• Customer segments: pharmaceutical companies (small molecules and biologics), biotech firms, academic and diagnostic customers.

• Contract development & manufacturing (CDMO) fees for custom peptides and APIs - typically long-term, higher-value contracts for clinical/commercial supply.
• Sale of catalogue peptides, reagents and biochemicals for research and diagnostics - recurring, volume-driven revenue.
• Value-added services: analytical, regulatory support, formulation and supply-chain solutions that command premium pricing.
• Geographic diversification and acquisitions that increase U.S. and global sales channels and capacity.

Bachem Holding AG (0QND.L): History

• Listed on the SIX Swiss Exchange under ticker BANB.
• Majority of shares are held by founder Peter Grogg, providing substantial strategic influence.
• Board of Directors includes Thomas Meier (CEO) and Dr. Peter Grogg H.C., Ph.D. as a director, balancing founder involvement with professional management.
• April 2025 Annual General Meeting attendance: 79.7% of eligible shares, signaling strong shareholder engagement.
• April 2025 dividend approved: CHF 0.85 per share.

• Governance: a structure that preserves founder influence while ensuring oversight by an experienced board to align with shareholder interests and support strategic decision-making.
• Shareholder approvals (April 2025): all proposals from the Board were approved, including the dividend payout.

Bachem Holding AG (0QND.L): Ownership Structure

• High quality supply: dedicated to providing high‑purity peptide and oligonucleotide products for research, clinical development and commercial applications.
• Innovation focus: aims to be a leading, innovation‑driven entity in biotechnology through continuous R&D and process development.
• Operational excellence: prioritizes efficiency measures and capacity expansion to meet rising market demand and reduce lead times.
• Sustainability: invests in environmentally responsible production facilities and process improvements to reduce waste, energy and emissions.
• Collaborative culture: more than 2,200 employees (global headcount) work across production, R&D, quality and commercial functions.
• Customer commitment: continuous improvement and stringent quality systems drive customer satisfaction and market competitiveness.

• Core offering: custom and catalog peptides and oligonucleotides produced to GMP and non‑GMP specifications for pharma, biotech and academic clients.
• Revenue model: fee‑for‑service manufacturing, captive process development, scale‑up for clinical and commercial supply, plus margin on proprietary intermediates and APIs.
• Value drivers: long development timelines create durable service contracts; high barriers to entry for GMP peptide/oligo production support pricing power.
• Capacity investments: recurring capital expenditure to add synthesizer lines, analytic capacity and new GMP suites to capture growing demand for advanced modalities.

• Free float: majority of shares are held by institutional investors and retail investors, enabling liquid public trading on the relevant exchange.
• Long‑term alignment: significant stakes held by family/inception‑era shareholders and long‑term institutions provide governance continuity and strategic visibility.
• Board & management: professional executive team and supervisory board focused on scaling capacity, maintaining GMP quality and deploying capex for future growth.

Bachem Holding AG (0QND.L): Mission and Values

• Core activities: process development, peptide and oligonucleotide manufacturing (R&D scale to commercial scale), analytical development, and regulatory support for peptide APIs.
• End-to-end services: feasibility studies, method transfer, scale-up, GMP manufacturing, release testing, and regulatory documentation support (CMC dossiers, batch release records).
• Customer base: global pharmaceutical and biotechnology companies developing therapeutics across oncology, endocrinology, metabolic disease and diagnostics.
• Quality focus: comprehensive quality control (QC) and quality assurance (QA) systems, GMP-certified production, and adherence to EMA, FDA and ICH guidelines.

• Headquarters and major site: Bubendorf, Switzerland - R&D, process development and commercial peptide manufacturing.
• Other European and US sites: Vionnaz (Switzerland), Vista and Torrance (California, USA) and St Helens (UK) - a mix of API manufacturing, process development and analytical labs.
• Strategic approach: optimize throughput at existing plants while developing greenfield and brownfield expansions to add capacity for peptide and oligonucleotide production.

• Planned investment: the company has announced plans to invest over CHF 400 million in 2025 to expand production capacity, upgrade facilities and increase oligonucleotide capabilities.
• Operational strategy: balanced approach between increasing yields at existing plants (process optimization, equipment upgrades) and constructing new modular production units to reduce time-to-scale.
• Workforce and training: recruitment of specialized operators, scientists and quality staff combined with targeted training programs to support GMP operations at scale.

• Revenue drivers: commercial peptide API sales, clinical manufacturing, custom development projects and regulatory support fees.
• Contract structure: mixture of fee-for-service and longer-term supply agreements for commercial APIs, yielding recurring revenue streams once products reach commercialization.
• Margin profile: typically higher margins on scale commercial manufacturing compared with early-development contracts; investment in capacity aims to convert rising clinical pipelines into stable commercial revenue.

• Regulatory compliance: GMP-certified sites, regular inspections by regulatory authorities (FDA/EMA/ MHRA) and strict change control and batch release processes.
• Quality systems: in-process controls, stability programs, validated analytical methods and electronic batch records to ensure traceability.
• Risk mitigation: geographic diversification of production sites, strategic inventory management, and capacity flexibility to address supply chain disruptions and customer demand shifts.

• Scale commercial manufacturing: converting clinical-stage programs into long-term commercial supply contracts to generate recurring, high-margin revenue.
• Expand oligonucleotide capabilities: capture a growing share of oligonucleotide therapeutics manufacturing through targeted capital spend and technical hiring.
• Operational excellence: improve yields and throughput at existing sites to lower unit costs and increase capacity utilization.
• Value-added services: provide early process development and regulatory support that lead to downstream manufacturing contracts and lifecycle management partnerships.

Bachem Holding AG (0QND.L): How It Works

• Core offerings: custom peptide and oligonucleotide synthesis, process development, GMP manufacturing, analytical and regulatory support.
• Customer mix: biotech innovators, large pharma, contract development and manufacturing organizations (CDMOs) and academic research centers.
• Product types: active pharmaceutical ingredients (APIs) for peptides and oligonucleotides, clinical trial material, and commercial supply batches.

• Commercial active ingredients (APIs): large-scale GMP manufacturing and long-term supply contracts for marketed drugs - high portion of revenue and higher margins.
• Process development & manufacturing services: FEED-to-GMP process transfer, scale-up and tech transfer projects billed as development fees and recurring manufacturing income.
• Research & specialties: smaller-scale custom syntheses, research reagents and early-phase materials billed per project or per unit.
• Regulatory and analytical services: stability studies, release testing and regulatory dossier support included in service contracts or invoiced separately.

• High-margin focus: emphasis on complex, higher-value peptides and oligonucleotides that command premium pricing compared with commodity chemicals.
• Scale efficiencies: multi-site manufacturing footprint and capacity utilization reduce per-unit costs and support stable gross margins.
• Long-term supply agreements: multi-year contracts with pharma customers convert development work into recurring commercial revenue.
• Value-added services: process development and regulatory support increase customer stickiness and create additional fee-based income streams.

• Capacity expansion: ongoing investment in new GMP suites and production lines to capture rising demand for peptide and oligonucleotide therapies.
• Technological upgrades: automation and analytical capabilities to improve yields, shorten cycle times and support complex chemistry at scale.
• Geographic footprint: multiple production and R&D sites to provide supply security and regulatory diversification for global customers.

Bachem Holding AG (0QND.L): How It Makes Money

• Core revenue streams: custom peptide synthesis, oligonucleotide manufacturing, development & analytical services, and license/supply contracts.
• Competitive edge: integrated peptide/oligo technology platforms, regulatory-compliant GMP capacity, and long-term partnerships with pharma clients.
• Strategic focus: innovation, capacity expansion, and operational excellence to serve growing biologics demand.